These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37062502)

  • 1. Apelin/ELABELA-APJ system in cardiac hypertrophy: Regulatory mechanisms and therapeutic potential.
    Pang B; Jiang YR; Xu JY; Shao DX; Hao LY
    Eur J Pharmacol; 2023 Jun; 949():175727. PubMed ID: 37062502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apelin/APJ system: A bifunctional target for cardiac hypertrophy.
    Lu L; Wu D; Li L; Chen L
    Int J Cardiol; 2017 Mar; 230():164-170. PubMed ID: 27979574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology.
    Kuba K; Sato T; Imai Y; Yamaguchi T
    Peptides; 2019 Jan; 111():62-70. PubMed ID: 29684595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.
    Sato T; Sato C; Kadowaki A; Watanabe H; Ho L; Ishida J; Yamaguchi T; Kimura A; Fukamizu A; Penninger JM; Reversade B; Ito H; Imai Y; Kuba K
    Cardiovasc Res; 2017 Jun; 113(7):760-769. PubMed ID: 28371822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting drugs to APJ receptor: From signaling to pathophysiological effects.
    Huang Z; He L; Chen Z; Chen L
    J Cell Physiol; 2018 Jan; 234(1):61-74. PubMed ID: 30070701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The functional role of endogenous APJ agonists; Apelin and Elabela/Toddler in cardiovascular diseases].
    Sato T; Kuba K
    Nihon Yakurigaku Zasshi; 2019; 153(4):172-178. PubMed ID: 30971657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanosensitive APJ internalization via clathrin-mediated endocytosis: A new molecular mechanism of cardiac hypertrophy.
    He L; Chen L; Li L
    Med Hypotheses; 2016 May; 90():6-10. PubMed ID: 27063076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biological function of ELABELA and APJ signaling in the cardiovascular system and pre-eclampsia.
    Liu Y; Wang L; Shi H
    Hypertens Res; 2019 Jul; 42(7):928-934. PubMed ID: 30626933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research Progress on Role and Mechanism of Elabela in Organ Fibrosis].
    Zhang Y; Luo PT; Li XY; Cui WP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Apr; 43(2):278-282. PubMed ID: 33966710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the elabela/apelin-apelin receptor axis as a novel therapeutic approach for hypertension.
    Song J; Tang J; Zhang Z; Liu Y; Zhong J
    Chin Med J (Engl); 2022 May; 135(9):1019-1026. PubMed ID: 34608073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APJ acts as a dual receptor in cardiac hypertrophy.
    Scimia MC; Hurtado C; Ray S; Metzler S; Wei K; Wang J; Woods CE; Purcell NH; Catalucci D; Akasaka T; Bueno OF; Vlasuk GP; Kaliman P; Bodmer R; Smith LH; Ashley E; Mercola M; Brown JH; Ruiz-Lozano P
    Nature; 2012 Aug; 488(7411):394-8. PubMed ID: 22810587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition.
    Parikh VN; Liu J; Shang C; Woods C; Chang AC; Zhao M; Charo DN; Grunwald Z; Huang Y; Seo K; Tsao PS; Bernstein D; Ruiz-Lozano P; Quertermous T; Ashley EA
    Am J Physiol Heart Circ Physiol; 2018 Aug; 315(2):H348-H356. PubMed ID: 29775410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Elabela-APJ axis: a promising therapeutic target for heart failure.
    Ma Z; Song JJ; Martin S; Yang XC; Zhong JC
    Heart Fail Rev; 2021 Sep; 26(5):1249-1258. PubMed ID: 32314083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elabela Peptide: An Emerging Target in Therapeutics.
    Sharma M; Prabhavalkar KS; Bhatt LK
    Curr Drug Targets; 2022; 23(14):1304-1318. PubMed ID: 36029072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of apelin and Elabela in cardiovascular disease.
    Gao S; Chen H
    Biomed Pharmacother; 2023 Oct; 166():115268. PubMed ID: 37562237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elabela-apelin-12, 17, 36/APJ system promotes platelet aggregation and thrombosis via activating the PANX1-P2X7 signaling pathway.
    Chen Z; Luo X; Liu M; Jiang J; Li Y; Huang Z; Wang L; Cao J; He L; Huang S; Hu H; Li L; Chen L
    J Cell Biochem; 2023 Apr; 124(4):586-605. PubMed ID: 36855998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APJ as Promising Therapeutic Target of Peptide Analogues in Myocardial Infarction- and Hypertension-Induced Heart Failure.
    Rossin D; Vanni R; Lo Iacono M; Cristallini C; Giachino C; Rastaldo R
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure.
    Gargalovic P; Wong P; Onorato J; Finlay H; Wang T; Yan M; Crain E; St-Onge S; Héroux M; Bouvier M; Xu C; Chen XQ; Generaux C; Lawrence M; Wexler R; Gordon D
    Circ Heart Fail; 2021 Mar; 14(3):e007351. PubMed ID: 33663236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apelin/APJ system as a therapeutic target in diabetes and its complications.
    Hu H; He L; Li L; Chen L
    Mol Genet Metab; 2016 Sep; 119(1-2):20-7. PubMed ID: 27650065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Apelinergic System: Apelin, ELABELA, and APJ Action on Cell Apoptosis: Anti-Apoptotic or Pro-Apoptotic Effect?
    Respekta N; Pich K; Dawid M; Mlyczyńska E; Kurowska P; Rak A
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.